Why Hims & Hers Health (HIMS) shares are getting obliterated today

What happened

Hims & Hers Health reported third-quarter 2026 revenue of $890.4 million, up 48.6% year over year, and GAAP earnings per share of negative 14 cents. It forecast fourth-quarter revenue of $885 million at the midpoint, below analyst expectations, while customer count declined from the previous quarter.

Confirmed

Global impact / market context

The sales forecast and lower customer count point to weaker near-term growth than analysts expected, while negative earnings per share and adjusted EBITDA below estimates suggest profitability also disappointed. If fewer customers or slower sales persist, revenue growth and cash available to fund operations could come under pressure.

Analyst inference

The article reports a sharp share-price decline following guidance below expectations, despite strong year-over-year revenue growth. That contrast suggests investors focused more on the next quarter’s sales outlook, profitability, and customer losses than on the reported revenue increase when reassessing the company’s prospects.

Analyst inference

What to watch

1. Check whether fourth-quarter revenue reaches the company’s $885 million midpoint forecast; the article says this outlook was below analysts’ $953.1 million estimate. Confirmed
2. Watch customer count in the next reported period: continued declines could limit sales growth, while stabilization would indicate that customer losses are easing. Analyst inference
3. Compare reported earnings and adjusted EBITDA with forecasts; adjusted EBITDA is a company performance measure that excludes some costs, and further shortfalls could signal profit pressure. Analyst inference

Evidence

• stockstory.org